Prevention of Stroke and Dementia in Primary Care

Stroke Clinical Trial

— INVADE  

Official title:

Intervention Project of Cerebrovascular Diseases and Dementia in the District of Ebersberg

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01107548
• Other study ID #: 080250hb
• Status: Terminated
• Phase: N/A
• First received: April 19, 2010
• Last updated: February 16, 2012
• Start date: January 2001
• Est. completion date: March 2010

Study information

• Verified date: April 2010
• Source: Technische Universität München
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: The Bavarian State Ministry of the Environment and Public Health
• Study type: Interventional

Clinical Trial Summary

In Western Countries, stroke and dementia are the main causes of long-term disability, dependency, and nursing home admission. Due to demographic trends a continuous increase of patient numbers can be expected.

There is growing evidence that vascular risk factors which are implicated in the etiology of stroke also play important etiologic roles in both vascular dementia and Alzheimer disease. The present project is aimed at the reduction of stroke and dementia by means of a systematic detection and subsequent treatment of vascular risk factors by the family doctor based on established guidelines.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3908
• Est. completion date: March 2010
• Est. primary completion date: December 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• Age 55 years or over

• Member of a particular health insurance plan (AOK)

• Resident of the district of Ebersberg

Exclusion Criteria:

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Dementia
• Disability
• Stroke

Intervention

Other:
• Systematic detection of vascular risk factors and subsequent evidence-based treatment

Locations

Country	Name	City	State
Germany	Depts. of Psychiatry and Neurology, Technische Universität München	Munich

Sponsors (9)

Lead Sponsor	Collaborator
Technische Universität München	Allgemeine Ortskrankenkasse Bayern (AOK), Bayer, Berlin-Chemie Menarini, Organon, Ratiopharm GmbH, Sanofi-Synthelabo, Stiftung Deutsche Schlaganfall-Hilfe, Teva Pharma GmbH

Country where clinical trial is conducted

Germany, 

References & Publications (3)

Sander D, Schulze-Horn C, Bickel H, Gnahn H, Bartels E, Conrad B. Combined effects of hemoglobin A1c and C-reactive protein on the progression of subclinical carotid atherosclerosis: the INVADE study. Stroke. 2006 Feb;37(2):351-7. Epub 2005 Dec 22. — View Citation

Sander K, Bickel H, Schulze Horn C, Huntgeburth U, Poppert H, Sander D. [Peripheral arterial disease: predictors and treatment intensity. Two-years of data from the population-based INVADE project]. Dtsch Med Wochenschr. 2008 Mar;133(10):455-9. doi: 10.10 — View Citation

Scherpinski U, Bickel H, Gnahn H, Förstl H, Conrad B, Sander D. [Intervention project on cerebrovascular diseases and dementia in the Ebersberg district (INVADE): rationale and design]. Nervenarzt. 2002 Dec;73(12):1199-204. German. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of long-term care disability		8 years	No
Primary	Incidence of stroke		8 Years	No
Secondary	Reduction of cardiovascular risk factors		8 years	No

External Links

•   Link